Asia Pacific Products In Later Stages Of Development Compared To Other Markets
This article was originally published in PharmAsia News
SHANGHAI - Late-stage development of innovative drugs has grown rapidly in Asia Pacific in recent years, but early-phase development continues to lag in the region as global companies face the limitations of development budgets
You may also be interested in...
SEOUL - The Korean clinical trial industry is hoping to distinguish itself as a draw for early-stage clinical trials, trying to find ground in a clinical trial environment that puts the focus on trial work in emerging markets in countries like China and India
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).